Abstract
According to Jacques Banchereau, PhD, director of Baylor Institute for Immunology Research (BIIR), the field of cancer vaccines is in a renaissance mode. Researchers at Baylor Dallas are exploring multiple strategies to overcome the difficulties involved in constructing therapeutic vaccines against various types of cancer. Dendritic cells, the primary antigen-presenting cells central to the cellular immune response, are being grown and manipulated in the laboratory for use as vaccines against cancer. Innovative molecular biology techniques are being used to unravel immune alterations in cancer as well as identify biomarkers of clinical efficacy. Modern approaches are being used to stimulate the immune response and to reduce or eliminate naturally occurring immune suppressive factors. And recombinant off-shelf vaccines based on tumor-specific antigens grown in plants are being tested in multi-institutional clinical trials.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
